CJC-1295 Dosage Guide
DAC vs no-DAC (Mod GRF 1-29) protocols — dose ranges, reconstitution, Ipamorelin stacking, cycling schedules, and what the research actually shows.
In This Guide
A leading innovator in research chemicals.
|Exclusive OfferUse our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.
Shop NowFor research purposes only. PeptideWiki may earn a commission at no extra cost to you.
CJC-1295
For research purposes only. PeptideWiki may earn a commission at no extra cost to you.
What Is CJC-1295?
CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) — the natural signal your hypothalamus sends to the pituitary gland to release growth hormone (GH). CJC-1295 consists of the first 29 amino acids of GHRH with four amino acid substitutions that make it resistant to enzymatic breakdown, dramatically extending its biological activity compared to native GHRH (which is degraded within minutes).
CJC-1295 exists in two fundamentally different versions that are not interchangeable:
| Feature | CJC-1295 No-DAC (Mod GRF 1-29) | CJC-1295 with DAC |
|---|---|---|
| Half-life | ~30 minutes | 6–8 days |
| GH Release Pattern | Sharp, pulsatile (mimics natural rhythm) | Sustained, elevated “bleed” effect |
| Injection Frequency | 2–3 times per day | 1–2 times per week |
| Typical Dose | 100 mcg per injection | 2 mg per injection |
| Pairs with GHRPs | Yes — standard practice (e.g., + Ipamorelin) | Not recommended — risk of overstimulation |
| Fasting Required | Yes — 2 hours before, 30 min after | Less critical but still advisable |
| Common Names | Mod GRF 1-29, Modified GRF, CJC no-DAC | CJC-1295 DAC, CJC-DAC |
Key Characteristics:
- GHRH analog — synthetic version of the first 29 amino acids of Growth Hormone Releasing Hormone, with four substitutions for enzymatic stability
- Two distinct versions — no-DAC (Mod GRF 1-29) has a ~30-minute half-life; DAC version binds to albumin extending the half-life to 6–8 days
- GH secretagogue — stimulates the pituitary to release endogenous growth hormone rather than introducing exogenous GH directly
- Synergistic with GHRPs — the no-DAC version is commonly stacked with GH-releasing peptides like Ipamorelin for amplified, pulsatile GH release
- Subcutaneous injection — administered via subcutaneous injection into abdominal or thigh fat; not an oral or topical peptide
- Research peptide — not FDA-approved for any medical use; classified as a research chemical in the United States
For a complete overview of its mechanism and research, see our full CJC-1295 profile. New to peptides? Start with the Beginner's Guide to Peptides.
How CJC-1295 Dosage Is Determined
CJC-1295 dosing is informed by clinical pharmacokinetic data, GH response studies, and over a decade of community experience. The two versions — DAC and no-DAC — have entirely separate evidence bases and dosing frameworks.
Clinical Trial Data (DAC Version)
The DAC version was studied in clinical trials by ConjuChem Biotechnologies. A dose-escalation study in healthy adults showed that single subcutaneous doses of 30–60 mcg/kg produced sustained GH elevation lasting 6+ days, with IGF-1 levels increasing 1.5–3x above baseline. The 60 mcg/kg dose (approximately 2–4 mg for most adults) produced the most robust and sustained response. Multiple weekly doses maintained elevated IGF-1 for the duration of the study.
Pharmacokinetic Data (No-DAC / Mod GRF 1-29)
The no-DAC version (Mod GRF 1-29) has a half-life of approximately 30 minutes. Studies on native GRF(1-29) and its modified analogs demonstrate that subcutaneous doses of 1–2 mcg/kg (approximately 70–150 mcg for most adults) produce a sharp GH pulse peaking at 15–30 minutes post-injection and returning to baseline within 1–2 hours. The GHRH receptor shows saturation kinetics — doses above ~150 mcg do not proportionally increase GH output.
Community Consensus
Based on years of anecdotal reporting and blood work sharing in peptide research communities, the standard no-DAC dose has converged at 100 mcg per injection, 2–3 times daily, almost always combined with Ipamorelin at 100 mcg. For DAC, the community standard is 2 mg once or twice weekly, used alone without daily GHRP stacking. These community doses align closely with the clinical PK data.
CJC-1295 No-DAC (Mod GRF 1-29) Dosage Ranges
Mod GRF 1-29 is dosed by injection in micrograms (mcg). The short half-life means multiple daily injections are required. Most users pair it with Ipamorelin at equal doses for synergistic GH release.
Dose Per Injection by Experience Level
| Level | Dose Per Injection | Frequency | Daily Total | Notes |
|---|---|---|---|---|
| Beginner | 100 mcg | 2x/day | 200 mcg | Start here to assess tolerance; pre-bed + morning fasted |
| Intermediate | 100 mcg | 3x/day | 300 mcg | Most common protocol; morning, post-workout, and pre-bed |
| Advanced | 100–150 mcg | 3x/day | 300–450 mcg | Diminishing returns above 100 mcg per injection; receptor saturation |
Weight-Based Reference Chart (No-DAC)
| Body Weight | Conservative (1 mcg/kg) | Standard (1.5 mcg/kg) | Upper Range (2 mcg/kg) |
|---|---|---|---|
| 60 kg (132 lb) | 60 mcg | 90 mcg | 120 mcg |
| 70 kg (154 lb) | 70 mcg | 100 mcg | 140 mcg |
| 80 kg (176 lb) | 80 mcg | 100 mcg | 150 mcg |
| 90 kg (198 lb) | 90 mcg | 100 mcg | 150 mcg |
| 100 kg (220 lb) | 100 mcg | 100 mcg | 150 mcg |
CJC-1295 DAC Dosage Ranges
CJC-1295 with DAC is dosed in milligrams (mg) because its extended half-life allows for much less frequent injections at higher absolute amounts. The DAC modification binds the peptide to serum albumin, creating a slow-release reservoir that sustains GH elevation for days.
Dose Per Injection by Experience Level
| Level | Dose Per Injection | Frequency | Weekly Total | Notes |
|---|---|---|---|---|
| Beginner | 2 mg | Once/week | 2 mg | Start here to assess tolerance; inject on the same day each week |
| Intermediate | 2 mg | Twice/week | 4 mg | Most common DAC protocol; e.g., Monday and Thursday |
| Advanced | 2–3 mg | Twice/week | 4–6 mg | Higher doses increase side effects; monitor blood work closely |
Weight-Based Reference Chart (DAC)
| Body Weight | Conservative (30 mcg/kg) | Standard (40 mcg/kg) | Upper Range (60 mcg/kg) |
|---|---|---|---|
| 60 kg (132 lb) | 1.8 mg | 2.4 mg | 3.6 mg |
| 70 kg (154 lb) | 2.1 mg | 2.8 mg | 4.2 mg |
| 80 kg (176 lb) | 2.4 mg | 3.2 mg | 4.8 mg |
| 90 kg (198 lb) | 2.7 mg | 3.6 mg | 5.4 mg |
| 100 kg (220 lb) | 3.0 mg | 4.0 mg | 6.0 mg |
Choosing DAC vs No-DAC
| Consideration | Choose No-DAC If... | Choose DAC If... |
|---|---|---|
| GH pattern preference | You want natural pulsatile GH release | You want sustained, consistent GH elevation |
| Injection tolerance | You are comfortable with 2–3 injections per day | You prefer 1–2 injections per week |
| Stacking with Ipamorelin | Yes — this is the “gold standard” combo | Not recommended with daily GHRP dosing |
| Side effect sensitivity | Lower risk of water retention and sustained sides | Higher risk of water retention, joint stiffness |
| Timing flexibility | Must be fasted; timing matters | Less timing-sensitive; inject any day, any time |
| Community preference | More widely used; more shared data | Less common; fewer anecdotal reports |
Calculate Your CJC-1295 Dose
After reconstituting your CJC-1295 with bacteriostatic water, you need to calculate how many units (on an insulin syringe) correspond to your target dose. The math depends on the vial size and the amount of water you add.
Worked Example: No-DAC (Mod GRF 1-29)
- Vial size: 2 mg (2,000 mcg) CJC-1295 no-DAC
- Bacteriostatic water added: 2 mL
- Concentration: 2,000 mcg ÷ 2 mL = 1,000 mcg/mL
- Target dose: 100 mcg
- Volume to inject: 100 mcg ÷ 1,000 mcg/mL = 0.1 mL = 10 units on a U-100 insulin syringe
- Doses per vial: 2,000 mcg ÷ 100 mcg = 20 doses
Worked Example: DAC Version
- Vial size: 2 mg (2,000 mcg) CJC-1295 DAC
- Bacteriostatic water added: 1 mL
- Concentration: 2,000 mcg ÷ 1 mL = 2,000 mcg/mL
- Target dose: 2 mg (2,000 mcg) — the full vial
- Volume to inject: 2,000 mcg ÷ 2,000 mcg/mL = 1 mL = 100 units on a U-100 insulin syringe
- Doses per vial: 1 dose (full vial per injection at 2 mg)
No-DAC Reconstitution Quick Reference
| Vial Size | Water Added | Concentration | 100 mcg Dose | Doses Per Vial |
|---|---|---|---|---|
| 2 mg | 1 mL | 2,000 mcg/mL | 5 units (0.05 mL) | 20 |
| 2 mg | 2 mL | 1,000 mcg/mL | 10 units (0.1 mL) | 20 |
| 5 mg | 2 mL | 2,500 mcg/mL | 4 units (0.04 mL) | 50 |
| 5 mg | 5 mL | 1,000 mcg/mL | 10 units (0.1 mL) | 50 |
Skip the Math — Use Our
Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.
CJC-1295 Reconstitution Guide
CJC-1295 is supplied as a lyophilized (freeze-dried) powder in a sealed sterile vial. It must be reconstituted with bacteriostatic water before use. The process is the same for both DAC and no-DAC versions.
Supplies Needed:
- CJC-1295 lyophilized vial (2 mg or 5 mg)
- Bacteriostatic water (BAC water) — preserved with 0.9% benzyl alcohol
- Alcohol swabs for vial tops
- U-100 insulin syringes (29–31 gauge, 0.5 mL or 1 mL)
- A separate syringe or needle for drawing BAC water (optional but helps preserve the insulin syringe needle)
Steps
Wash Hands & Prepare Workspace
Wash hands thoroughly. Ensure workspace is clean and uncluttered. Lay out all supplies.
Swab Both Vials
Use an alcohol swab to clean the rubber stopper of both the peptide vial and the bacteriostatic water vial. Allow to air dry for 10 seconds.
Draw Bacteriostatic Water
Using a syringe, draw the desired amount of BAC water. For a 2 mg vial, 1–2 mL is standard. For a 5 mg vial, 2–5 mL works well.
Inject Water into the Peptide Calculator Vial
Insert the needle into the peptide vial at an angle, aiming the stream of water at the glass wall — not directly onto the powder cake. Let the water drip gently down the side.
Swirl Gently — Never Shake
Gently tilt and rotate the vial to dissolve the powder. Do NOT shake, vortex, or agitate vigorously — this can damage the peptide through mechanical stress and foaming.
Verify Complete Dissolution
The solution should be clear and free of visible particles. If powder remains, let the vial sit for 5–10 minutes and swirl again. Do not use if the solution is cloudy or contains debris.
Label & Refrigerate
Label the vial with the date, peptide name, concentration (e.g., 1,000 mcg/mL), and water volume. Store refrigerated at 2–8°C. Use within 4–6 weeks.
Storage
- Unreconstituted (powder): Store refrigerated (2–8°C) or frozen (−20°C) for extended storage. Stable for months when kept cold and dry.
- Reconstituted (liquid): Refrigerate at 2–8°C. Use within 4–6 weeks. Do not freeze reconstituted peptide.
- Protect from light and heat — store in the original amber vial or wrap in foil. Temperatures above 25°C accelerate degradation.
For a detailed step-by-step walkthrough with images, see our Reconstitution Guide.
CJC-1295 Dosage by Goal
Both CJC-1295 versions stimulate endogenous GH release, but different goals call for different protocols, version choices, and stacking strategies.
General GH Optimization (No-DAC + Ipamorelin)
The most common use case. Combining CJC-1295 no-DAC with Ipamorelin amplifies pulsatile GH release — the GHRH analog primes the pituitary while the GHRP triggers the pulse. This stack supports improved sleep quality, body composition, recovery, and skin health.
- Protocol: 100 mcg CJC no-DAC + 100 mcg Ipamorelin, 2–3x/day
- Timing: Morning fasted, post-workout, and 30 minutes before bed
- Cycle: 8–12 weeks on, 4 weeks off
- Expected results: Improved sleep (1–2 weeks), body composition changes (4–8 weeks), full effects at 3+ months
Fat Loss
Growth hormone is a potent lipolytic hormone. Elevated GH levels increase fatty acid oxidation and promote lean body mass. CJC-1295 no-DAC + Ipamorelin, dosed fasted, takes advantage of the synergy between fasting-induced GH release and peptide-stimulated GH pulses.
- Protocol: 100 mcg CJC no-DAC + 100 mcg Ipamorelin, 3x/day
- Timing: Morning fasted (before cardio if possible), mid-afternoon fasted, and pre-bed
- Cycle: 12 weeks on, 4 weeks off
- Notes: Combine with caloric deficit and resistance training for maximum fat loss
Anti-Aging & Convenience (DAC)
For users focused on general anti-aging benefits — skin quality, joint health, sleep — who want minimal injection burden, CJC-1295 DAC provides sustained GH elevation with only 1–2 injections per week. The trade-off is less physiological GH pulsing and a higher risk of water retention.
- Protocol: 2 mg CJC-1295 DAC, once or twice weekly
- Timing: Same day each week; time of day is less critical
- Cycle: 8–12 weeks on, 4–8 weeks off
- Notes: Do not add daily Ipamorelin; use DAC alone for this goal
Injury Recovery (Triple Stack)
GH accelerates tissue repair. For injury recovery, CJC-1295 no-DAC + Ipamorelin can be combined with BPC-157 for a comprehensive recovery stack. BPC-157 provides localized tissue-healing effects while the GH secretagogue stack provides systemic recovery support.
- Protocol: 100 mcg CJC no-DAC + 100 mcg Ipamorelin (2–3x/day) + 250–500 mcg BPC-157 (2x/day near injury site)
- Timing: CJC/Ipamorelin fasted; BPC-157 can be taken with or without food
- Cycle: 4–8 weeks or until recovery is complete
- Notes: BPC-157 does not require fasting and can be injected subcutaneously near the injury site
Muscle Growth & Performance
GH supports muscle protein synthesis, nitrogen retention, and recovery between training sessions. For muscle growth, the no-DAC + Ipamorelin stack at full 3x/day dosing provides the strongest pulsatile GH stimulus. Combining with resistance training and adequate protein intake is essential.
- Protocol: 100 mcg CJC no-DAC + 100 mcg Ipamorelin, 3x/day
- Timing: Morning fasted, immediately post-workout (wait 30 min before eating), and pre-bed
- Cycle: 12 weeks on, 4 weeks off
- Notes: Not a replacement for anabolic steroids; GH supports lean mass and recovery but produces much subtler hypertrophy effects
CJC-1295 Injection Guide
Subcutaneous Injection Protocol
Wash Hands
Wash hands thoroughly with soap and water. Prepare a clean workspace with supplies laid out.
Swab the Vial & Injection Site
Use an alcohol swab on the vial’s rubber stopper. Use a second swab on the injection site. Allow to air dry for 10 seconds.
Draw the Peptide
Insert the needle into the vial and draw the calculated dose. If combining CJC no-DAC + Ipamorelin, draw from both vials into the same syringe (see below).
Remove Air Bubbles
Hold the syringe needle-up and tap gently to move any air bubbles to the top. Push the plunger slightly to expel the air.
Pinch & Insert
Pinch a fold of skin at the injection site (abdomen or outer thigh). Insert the needle at a 45–90° angle into the subcutaneous fat layer.
Inject & Withdraw
Depress the plunger slowly and steadily. Wait 5 seconds after the plunger is fully depressed, then withdraw the needle smoothly. Do not rub the injection site.
Dispose Safely
Place the used syringe directly into a sharps container. Never recap needles. Rotate injection sites between doses to prevent lipohypertrophy.
Mixing CJC-1295 No-DAC + Ipamorelin in One Syringe
This is standard practice and eliminates the need for two separate injections per dose. Both peptides are chemically compatible in the same solution for the short time between drawing and injecting.
Procedure:
- Swab both vials (CJC-1295 no-DAC and Ipamorelin) with alcohol
- Draw the calculated dose of CJC-1295 no-DAC first (e.g., 10 units at 1,000 mcg/mL = 100 mcg)
- Without changing the syringe, insert into the Ipamorelin vial and draw the calculated dose (e.g., another 10 units at 1,000 mcg/mL = 100 mcg)
- Total syringe volume is now 20 units containing 100 mcg CJC + 100 mcg Ipamorelin
- Inject subcutaneously as described above
Injection Sites
- Abdominal fat (preferred): 2 inches from the navel in any direction. Best absorption for subcutaneous peptides.
- Outer thigh: Mid-thigh, outer quadrant. Good alternative when rotating away from the abdomen.
- Rotate sites: Alternate between left and right sides and different areas within each site to prevent lipohypertrophy (localized fat pad changes from repeated injection).
Cycle Duration & Timing
CJC-1295 should be cycled to prevent pituitary desensitization. The on/off periods differ between DAC and no-DAC due to their different pharmacokinetics.
No-DAC (Mod GRF 1-29) Cycling
| Protocol | On Period | Off Period | Notes |
|---|---|---|---|
| Standard cycle | 8–12 weeks | 4 weeks | Most common; adequate for GH axis recovery |
| Extended cycle | 16 weeks | 4–6 weeks | For experienced users with blood work monitoring |
| 5-on / 2-off weekly | 5 days/week | 2 days/week | Weekdays on, weekends off; some users prefer this rhythm |
| Recovery-focused | 4–8 weeks | N/A | Run until injury recovery is complete, then discontinue |
DAC Cycling
| Protocol | On Period | Off Period | Notes |
|---|---|---|---|
| Standard DAC cycle | 8–12 weeks | 4–8 weeks | Longer off period due to DAC's sustained GH elevation |
| Conservative DAC cycle | 8 weeks | 6–8 weeks | Recommended for first-time DAC users |
Timing Recommendations
No-DAC (Mod GRF 1-29) — Timing Matters:
- Morning (fasted): Upon waking, before breakfast. Fast at least 2 hours prior (overnight fast handles this).
- Post-workout: Immediately after training, before the post-workout meal. Wait 30 minutes before eating.
- Pre-bed (most important): 30 minutes before sleep, at least 2 hours after your last meal. This dose synergizes with the natural nocturnal GH surge.
DAC — Timing Is Flexible:
- Inject on the same day(s) each week for consistency (e.g., Monday, or Monday + Thursday)
- Time of day is less critical due to the sustained-release mechanism
- Avoiding food around injection is still reasonable but not as critical as with no-DAC
CJC-1295 Stacking Protocols
CJC-1295 no-DAC is almost never used alone — its primary value comes from stacking with GH-releasing peptides (GHRPs) that work through a complementary mechanism. The GHRH analog (CJC) primes the pituitary while the GHRP triggers the GH release, producing a synergistic pulse that is significantly larger than either peptide alone.
CJC-1295 No-DAC + Ipamorelin — “The Gold Standard”
This is the most widely used GH peptide stack in the world. Ipamorelin is a selective GH-releasing peptide that triggers GH release without significantly raising cortisol or prolactin (unlike GHRP-6 or GHRP-2). When combined with CJC-1295 no-DAC, the two peptides produce a large, clean GH pulse with minimal side effects.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| CJC-1295 (no-DAC) | 100 mcg | 2–3x/day, fasted | GHRH analog; primes the pituitary for GH release |
| Ipamorelin | 100 mcg | 2–3x/day, with CJC | GHRP; triggers the GH pulse |
CJC-1295 No-DAC + Ipamorelin + BPC-157 (Recovery Stack)
Adding BPC-157 to the CJC/Ipamorelin stack creates a powerful recovery protocol. BPC-157 provides localized tissue healing (tendons, ligaments, gut) while the GH stack provides systemic recovery support. BPC-157 has a different mechanism and does not require fasting.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| CJC-1295 (no-DAC) | 100 mcg | 2–3x/day, fasted | GHRH analog; systemic GH elevation |
| Ipamorelin | 100 mcg | 2–3x/day, with CJC | GHRP; amplifies GH pulse |
| BPC-157 | 250–500 mcg | 2x/day (near injury site) | Localized tissue repair, gut healing |
CJC-1295 No-DAC + Ipamorelin + Sermorelin (Enhanced GHRH Stack)
Sermorelin is another GHRH analog with a slightly different receptor binding profile. Some users add low-dose Sermorelin to the CJC/Ipamorelin stack for potentially broader GHRH receptor activation. This is an advanced stack with less community data than the standard CJC + Ipamorelin protocol.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| CJC-1295 (no-DAC) | 100 mcg | 2–3x/day, fasted | Primary GHRH analog |
| Ipamorelin | 100 mcg | 2–3x/day, with CJC | GHRP trigger |
| Sermorelin | 100–200 mcg | Pre-bed dose only | Complementary GHRH analog |
Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.
Safety, Side Effects & Contraindications
Common Side Effects (Both Versions)
- Mild flushing or warmth after injection — especially with the no-DAC version; typically resolves within 15–30 minutes
- Headache — usually transient; can indicate the dose is too high
- Injection site irritation — redness, mild swelling, or itching at the injection site
- Increased hunger — GH stimulates appetite in some users
- Vivid dreams or improved sleep depth — especially with pre-bed dosing; generally considered a positive effect
- Mild water retention — temporary, usually subsides after 2–4 weeks
DAC-Specific Side Effects
The DAC version produces sustained GH elevation, which amplifies certain GH-related side effects compared to the pulsatile no-DAC version:
- More pronounced water retention — due to continuous GH elevation rather than brief pulses
- Joint stiffness or mild joint pain — GH can cause fluid accumulation in joints
- Carpal tunnel-like symptoms — numbness or tingling in hands, especially at higher doses
- Potential for greater insulin resistance — sustained GH elevation has a stronger anti-insulin effect than pulsatile release
Contraindications
- Active cancer or history of cancer — GH and IGF-1 can promote the growth of existing malignancies
- Diabetic retinopathy — elevated GH/IGF-1 can worsen proliferative retinopathy
- Pregnancy and breastfeeding — no safety data available
- Active pituitary tumors or pituitary disorders
- Uncontrolled diabetes — GH impairs insulin sensitivity
- Under 25 years old — natural GH production is still robust; supplementation is unnecessary and could interfere with normal development
Drug Interactions
- Insulin and oral hypoglycemics — GH raises blood glucose; diabetic patients may need to adjust insulin doses
- Corticosteroids — may blunt GH response and create conflicting metabolic effects
- Thyroid medications — GH can accelerate T4 to T3 conversion, potentially requiring thyroid dose adjustment
Blood Markers to Monitor
- IGF-1 — confirms GH axis stimulation; target is the upper normal range for your age, not above
- Fasting glucose & HbA1c — monitors insulin sensitivity; watch for elevation
- Comprehensive metabolic panel — kidney and liver function
- TSH and Free T4 — prolonged GH elevation can affect thyroid function
- Baseline labs before starting and follow-up at 6–8 weeks
Common CJC-1295 Mistakes
The DAC vs no-DAC distinction creates unique opportunities for dosing errors. Here are the most common mistakes and why they matter:
Frequently Asked Questions
Key Takeaways
- CJC-1295 exists in two versions — no-DAC (Mod GRF 1-29) with a ~30-minute half-life, and DAC with a 6–8-day half-life. They are NOT interchangeable.
- No-DAC standard dose: 100 mcg subcutaneously, 2–3x/day, fasted. Almost always combined with Ipamorelin at 100 mcg.
- DAC standard dose: 2 mg subcutaneously, 1–2x/week. Used alone without daily GHRP stacking.
- Gold standard stack: CJC-1295 no-DAC + Ipamorelin — the most widely used and best-documented GH peptide combination
- Fasting is critical for no-DAC — 2 hours before and 30 minutes after injection. Pre-bed dose is the highest-priority timing.
- Cycle: 8–12 weeks on, 4 weeks off (no-DAC); 8–12 weeks on, 4–8 weeks off (DAC)
- Monitor blood work: IGF-1, fasting glucose, HbA1c, and thyroid function at baseline and 6–8 weeks
- Not FDA-approved — classified as a research chemical. Banned by WADA. Consult a healthcare provider before use.
This article is for educational and informational purposes only. See our Disclaimer.
References
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
- Ionescu M, Bhatt DL, et al. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. 2006;91(12):4792-4797. PubMed
- Alba M, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PubMed
- Sackmann-Sala L, et al. “Pharmacological and physiological aspects of growth hormone releasing peptides.” Endocr Dev. 2010;17:22-35.
- Veldhuis JD, et al. “Mechanisms and regulators of growth hormone secretion.” Endocrinol Metab Clin North Am. 2007;36(1):75-100.
- Nass R, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.” Ann Intern Med. 2008;149(9):601-611. PubMed
Next Steps
Continue your research with these resources.